JPWO2021026454A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021026454A5
JPWO2021026454A5 JP2022507799A JP2022507799A JPWO2021026454A5 JP WO2021026454 A5 JPWO2021026454 A5 JP WO2021026454A5 JP 2022507799 A JP2022507799 A JP 2022507799A JP 2022507799 A JP2022507799 A JP 2022507799A JP WO2021026454 A5 JPWO2021026454 A5 JP WO2021026454A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
dose
administered
cfg920
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022507799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543679A (ja
JP2022543679A5 (https=
JP7526783B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045410 external-priority patent/WO2021026454A1/en
Publication of JP2022543679A publication Critical patent/JP2022543679A/ja
Publication of JP2022543679A5 publication Critical patent/JP2022543679A5/ja
Publication of JPWO2021026454A5 publication Critical patent/JPWO2021026454A5/ja
Application granted granted Critical
Publication of JP7526783B2 publication Critical patent/JP7526783B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022507799A 2019-08-08 2020-08-07 癌を処置する方法 Active JP7526783B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019099754 2019-08-08
CNPCT/CN2019/099754 2019-08-08
PCT/US2020/045410 WO2021026454A1 (en) 2019-08-08 2020-08-07 Method of treating cancer

Publications (4)

Publication Number Publication Date
JP2022543679A JP2022543679A (ja) 2022-10-13
JP2022543679A5 JP2022543679A5 (https=) 2023-08-10
JPWO2021026454A5 true JPWO2021026454A5 (https=) 2023-08-10
JP7526783B2 JP7526783B2 (ja) 2024-08-01

Family

ID=72234946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507799A Active JP7526783B2 (ja) 2019-08-08 2020-08-07 癌を処置する方法

Country Status (12)

Country Link
US (2) US20210038578A1 (https=)
EP (1) EP4009969A1 (https=)
JP (1) JP7526783B2 (https=)
KR (1) KR20220047589A (https=)
CN (1) CN114080225A (https=)
AU (1) AU2020327022B2 (https=)
BR (1) BR112022001508A2 (https=)
CA (1) CA3148115A1 (https=)
IL (1) IL289811A (https=)
MX (1) MX2022001450A (https=)
TW (1) TWI857119B (https=)
WO (1) WO2021026454A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7010330B1 (en) 2003-03-01 2006-03-07 Theta Microelectronics, Inc. Power dissipation reduction in wireless transceivers
US20250032504A1 (en) * 2021-11-27 2025-01-30 Transthera Sciences (Nanjing), Inc. Novel application of kinase inhibitor
US20250177352A1 (en) 2022-03-14 2025-06-05 Laekna Limited Combination treatment for cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
LT2656842T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US20110288142A1 (en) * 2009-01-30 2011-11-24 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
UY32730A (es) * 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
RU2014154009A (ru) * 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
ES3063787T3 (en) * 2013-10-01 2026-04-20 Novartis Ag Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
US10265329B2 (en) * 2015-03-06 2019-04-23 The Cleveland Clinic Foundation Altering steroid metabolism for treatment of steroid-dependent disease

Similar Documents

Publication Publication Date Title
US20240299381A1 (en) Methods of administering elagolix
CN103945849B (zh) 癌症的联合治疗
JP2022185091A (ja) 癌を治療するための方法及び組成物
US20110124617A1 (en) Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
JP2010077158A (ja) ホルモン−依存性疾病の予防及び処理のための抗黄体ホルモンの使用
JP2019529574A5 (https=)
JP2019529581A5 (https=)
TW202333675A (zh) 用於治療癌症之組合療法之用途
JP2023175688A5 (https=)
JP2024102045A5 (https=)
CN1658904A (zh) 包含埃坡霉素的组合及其药学用途
MX2015005160A (es) Trans-clomifeno para uso en terapia de cancer.
JP2001139474A (ja) コルチコイド療法
JPWO2020118252A5 (https=)
JPWO2021026454A5 (https=)
CN1747736A (zh) 包含芳化酶抑制剂、孕激素和雌激素组合的组合物及其治疗子宫内膜异位症的用途
CN111315378A (zh) 包含lsz102和瑞博西尼的药物组合
CN114903902A (zh) GnRH受体拮抗剂联合雄激素受体拮抗剂在制备治疗前列腺癌药物中的用途
WO2021034335A1 (en) Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers
WO2019174590A1 (zh) 用于治疗三阴性乳腺癌的喹啉衍生物
WO2023147134A2 (en) Methods for treating patients having low estrogen with nk3 antagonists
WO2023147135A1 (en) Nk receptor antagonists for treatment of prostate cancer
US20080261929A1 (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
US20230381154A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib
WO2026024933A1 (en) Cdk inhibitors and their use as pharmaceuticals